PINX: CRXM
- Last Close 0
- Sector Healthcare
- Industry Biotechnology
- Investment Style
- Day Range < 0.01 – < 0.01
- Year Range < 0.01 – < 0.01
- Market Cap 6,493.1888
- Volume / Avg 62,896.0 / 36,358.4
- Price / Sales —
- Price / Book —
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis CRXM
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile CRXM
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
FAQs for Gene Biotherapeutics Inc Stock
No. CRXM does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
CRXM’s market cap is 6,493.19.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
CRXM’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare CRXM’s historical performance against its industry peers and the overall market.